
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
The American Journal of Managed Care
over 23 years ago
Restoring Trust to Managed Care, Part 2: A Focus on Physiciansover 23 years ago
Review of the Newer Antiepileptic Drugs





